


For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk
<b>Format:</b>	Unconjugated		
<b>Cross Reactivity:</b>	Predicted to work with mouse, rat and other homologues.		
<b>Formulation:</b>	1X PBS, 0.09% NaN <sub>3</sub> , 0.2% BSA		
<b>Preparation:</b>	Protein A+G		
<b>Reactivity:</b>	Human		
<b>Recommended Usage:</b>	For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.		
<b>Immunogen:</b>	human recombinant ST2-Fc		
<b>Description:</b>	<p>Suppression of tumorigenicity (ST)2 is an interleukin (IL)-1 receptor family member and due to alternative splicing and 3' processing at RNA level, ST2 is expressed as soluble (sST2) as well as trans-membrane (ST2L) isoforms (1). Originally identified in 1989 as an orphan receptor, the ST2 ligand was identified to be IL-33 in 2005 (2). IL-33 is mechanically induced in cardiac fibroblasts and antagonizes hypertrophic stimuli. Analysis of rat neonatal cardiac fibroblasts and cardiomyocytes indicate that gene expression of IL-33 and sST2 was more than 5-fold greater in cardiac fibroblasts than in cardiomyocytes (3,4). Expression sST2 is markedly increased as early as 1 hr following mechanical strain in cultured myocytes and in patients with acute myocardial infarction (5).</p> <p>In addition, IL-33 behaves as a chromatin-related nuclear interleukin, and act as transcriptional repressor when overexpressed in cells (4). IL-33 production may be augmented by inflammation (6). IL-33 has been demonstrated to participate in several forms of inflammatory diseases and to influence tumorigenesis. IL-33 was identified to be pro-cancer mediator, since the activation pathway of IL-33/ST2 could promote metastasis (7).</p>		
<b>References:</b>	<ol style="list-style-type: none"> <li>1. Schmitz J, et al., (2005) Immunity, 23: 479-490.</li> <li>2. Dinarello CA, (2005), Immunity, 23: 461-462.</li> <li>3. Weinberg EO, et al., (2003), Circulation, 107: 721-726</li> <li>4. Sanada S. et al., (2007), J Clin Invest, 117: 1538-1549.</li> <li>5. Shimpo M., et al., (2004), Circulation, 109: 2186-2190.</li> <li>6. Kim S., al at., (2011), Ann N.Y. Acad. Sci., 1217:191-206.</li> <li>7. Afferri C., et al., (2018), Front Immunol, 9: 2601. doi:10.3389/fimmu.2018.02601</li> </ol>		



Flow cytometric analysis of HEK-Blue cells unstained cells (blue), stained with secondary antibody (red) or stained using ST2/IL-33R antibody (green), ST2IL33R-H2 at 1.0 ug/mL. Cat# 2477.